The statistical and clinical investigation of HBeAg/anti-HBe system in patients with HBe antigen-positive chronic hepatitis type B treated with antiviral and immunoregulatory therapies.

概要

論文の詳細を見る
Effects of adenine arabinoside (Ara-A, n=10), steroid withdrawal (n=12) and a combination of these two therapies (n=12) on serum HBeAg positivity were statistically studied in patients with chronic hepatitis type B, as compared with the patients with chronic hepatits type B treatd without any specific therapies (control, n=32). Cumulative induction curves of seronegative (SN) or seroconversion (SC) for HBeAg were simulated by Weibull analysis. Following results were obtained: 1) Annual SN rates were significantly higher in Ara-A, steroid withdrawal and combination therapy than in control (p<0.05). 2) The first induction of SN occured significantly earlier than in Ara-A, steroid withdrawal and combination therapy when compared to control (p<0.05). 3) In patients with initial GPT values above 200IU/l, SN was inducted significantly faster as well as earlier in treated group compared to control. In contrast, in patients with GPT value below 200IU/l, SN induction rate was similar between the two groups. 4) Cumulative curve of each treatment consisted of the first component with steeper slope and the second component with milder one. The transition point between the two components appeared around 6-7.5 months. The effect of each treatment was always exerted only on the first part, but not on the second component. In conclusion, those therapies should be targetted on patients with GPT above 200IU/l. In addition, patients without response to one treatment beyond 6-7.5 months will possibly be treated successfully by introducing another therapy.

The statistical and clinical investigation of HBeAg/anti-HBe system in patients with HBe antigen-positive chronic hepatitis type B treated with antiviral and immunoregulatory therapies.

スポンサーリンク

概要

著者

関連論文

スポンサーリンク